Revelation Biosciences (FRA:56U0) Ending Cash Position : €13.39 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Ending Cash Position?

Revelation Biosciences's Ending Cash Position for the quarter that ended in Mar. 2024 was €13.39 Mil.

Revelation Biosciences's quarterly Ending Cash Position declined from Sep. 2023 (€13.11 Mil) to Dec. 2023 (€11.00 Mil) but then increased from Dec. 2023 (€11.00 Mil) to Mar. 2024 (€13.39 Mil).

Revelation Biosciences's annual Ending Cash Position increased from Dec. 2021 (€1.13 Mil) to Dec. 2022 (€4.96 Mil) and increased from Dec. 2022 (€4.96 Mil) to Dec. 2023 (€11.00 Mil).

Revelation Biosciences Ending Cash Position Historical Data

The historical data trend for Revelation Biosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Ending Cash Position Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

1.13

4.96

11.00

Revelation Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial								16.54	14.50	13.11	11.00	13.39

Revelation Biosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Revelation Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	4.817	+	6.18
	=	11.00

Revelation Biosciences's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	11.032	+	2.356
	=	13.39

Revelation Biosciences Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences (FRA:56U0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

REVB:USA 56U1:Germany

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines